摘要
目的:初步探讨健脾消癌方降低结肠癌5-氟尿嘧啶(5-Fu)耐药作用机制。方法:将肠癌5-Fu耐药细胞移植到裸鼠腋窝建立耐药移植瘤模型,成瘤后将裸鼠按给药分组:模型组、5-Fu组、健脾消癌方组、健脾消癌方+5-Fu组。干预5周。观察各组的裸鼠体质量、肿瘤生长(瘤体积增长)、瘤重,检测磷酸酯酶与张力蛋白同源物(PTEN)、存活蛋白(Survivin)的表达。结果:健脾消癌方及健脾消癌方联合5-Fu组裸鼠体质量增加明显,与模型组和5-Fu组比较,差异均有统计学意义(均P<0.05)。健脾消癌方和健脾消癌方联合5-Fu组均明显抑制耐药移植瘤体生长,与模型组及5-Fu组比较,差异均有统计学意义(均P<0.05)。健脾消癌方和健脾消癌方联合5-Fu组升高PTEN蛋白、降低Survivin蛋白表达,与模型组比较,差异均有统计学意义(均P<0.05)。结论:健脾消癌方联合化疗可稳定肠癌模型裸鼠体质量,抑制肠癌耐药移植瘤生长,可能与升高PTEN蛋白、降低Survivin蛋白表达相关。
Objective:To preliminarily explore the mechanism by which the Jianpi Xiaoai Prescription reduces the resistance to 5-fluorouracil(5-Fu) in colon cancer.Methods:The 5-Fu-resistant colon cancer cells were transplanted into the axilla of nude mice to establish a drug-resistant tumor model.Once tumors were established,the mice were divided into four groups based on the treatment:model group,5-Fu group,Jianpi Xiaoai Prescription group,and Jianpi Xiaoai Prescription+5-Fu group.The intervention lasted for 5 weeks.The body weight,tumor growth(tumor volume),and tumor weight of the mice were observed.The expression levels of phosphatase and tensin homolog(PTEN) and Survivin were measured.Results:The body weight of mice in the Jianpi Xiaoai Prescription and Jianpi Xiaoai Prescription+5-Fu groups increased significantly compared with the model and 5-Fu groups(P<0.05).Both the Jianpi Xiaoai Decoction and Jianpi Xiaoai Prescription+5-Fu groups significantly inhibited the growth of drug-resistant transplanted tumors,with statistically significant differences compared with the model and 5-Fu groups(P<0.05).The PTEN protein expression was increased,and Survivin protein expression was decreased in the Jianpi Xiaoai Prescription and Jianpi Xiaoai Prescription+5-Fu groups,with significant differences compared with the model group(P<0.05).Conclusion:Jianpi Xiaoai Prescription combined with chemotherapy can stabilize the body weight of colon cancer model nude mice and inhibit the growth of drug-resistant transplanted tumors.This effect may be related to the upregulation of PTEN protein and downregulation of Survivin protein expression.
作者
寇胜兰
陈思勤
杨家翔
宁康文
汪紫琪
谭愉琴
周婉双
彭巍
简小兰
KOU Shenglan;CHEN Siqin;YANG Jiaxiang;NING Kangwen;WANG Ziqi;TAN Yuqin;ZHOU Wanshuang;PENG Wei;JIAN Xiaolan(Graduate School,Hunan University of Chinese Medicine,Changsha 410208,China;The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine,Changsha 410006,China)
出处
《世界中医药》
北大核心
2025年第6期961-965,共5页
World Chinese Medicine
基金
国家自然科学基金项目(81904109)
湖南省自然科学基金项目(2023JJ30361)
湖南省中医药管理局项目(B2023083)。
